This podcast is a follow-up to Bayer’s symposium at ESC 2022, ‘The beginning of the end for NOACs? The extra mile’.

In this episode, Dr Manesh Patel and Professor Rupert Bauersachs expand on the discussions from the symposium, providing further insight into the management of frail patients with AF and VTE. The experts also provide their perspectives on the treatment of paediatric patients with VTE and patients with cancer-associated thrombosis, evaluating the available evidence to guide decision-making for these particularly vulnerable patients.

The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer.

Further details:• The EINSTEIN programme publications can be found here for EINSTEIN PE (https://www.nejm.org/doi/full/10.1056/NEJMoa1113572), EINSTEIN DVT (https://www.nejm.org/doi/full/10.1056/NEJMoa1007903), EINSTEIN Pooled (https://thrombosisjournal.biomedcentral.com/articles/10.1186/1477-9560-11-21), EINSTEIN CHOICE (https://www.nejm.org/doi/full/10.1056/nejmoa1700518) and EINSTEIN JUNIOR (https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30219-4/fulltext)• Real-world evidence published by Craig Coleman on the efficacy and safety of rivaroxaban versus warfarin in frail patients with VTE can be accessed here: https://www.amjmed.com/article/S0002-9343(18)30202-X/fulltext• The XALIA study publication can be found here: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(15)00257-4/fulltext• The findings from the XANTUS trial are available here: https://academic.oup.com/eurheartj/article/37/14/1145/2466063• Access the ROCKET AF manuscript here: https://www.nejm.org/doi/full/10.1056/nejmoa1009638• The elderly subgroup analysis of ROCKET AF can be found here: https://www.ahajournals.org/doi/10.1161/circulationaha.113.005008• Findings from the SAFIR trial can be accessed here: https://heart.bmj.com/content/107/17/1376• Find the edoxaban phase II trial paper here: https://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH10-01-0066• Read the SELECT-D study paper here: https://ascopubs.org/doi/10.1200/JCO.2018.78.8034• Information on the OSCAR trials can be found here for the UK (https://clinicaltrials.gov/ct2/show/NCT05112666, https://abstracts.isth.org/abstract/comparison-of-effectiveness-and-safety-of-direct-oral-anticoagulant-versus-low-molecular-weight-heparin-treatment-for-venous-thromboembolism-in-patients-with-active-cancer-the-oscar-uk-study/) and the US (https://clinicaltrials.gov/ct2/show/NCT04979780, https://www.sciencedirect.com/science/article/pii/S0006497121040908)• Details on the Mayo Clinic prospective cohort study are available here: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00435-3/fulltext• Support for the proportion of patients not receiving anticoagulation can be accessed here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278389/#CIT0011• For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc)

Audio: MA-M_RIV-ALL-1236-1Shownotes: MA-M_RIV-ALL-1237-1